BioPharma Resources

Drug Trial Radar · NCT04557449

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Sep 23, 2020

Primary completion

Oct 7, 2029

Study completion Oct 7, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort. Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion. In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted. In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI). In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide. In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE. Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060. Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively. Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy. Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen. The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK. The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.

Conditions

  • Liposarcoma
  • Prostate Cancer
  • Advanced Breast Cancer
  • NSCLC (Non-small Cell Lung Cancer)
  • Colorectal Cancer

Interventions

  • PF-07220060Drug

    CDK4 inhibitor

  • LetrozoleCombination product

    Endocrine Therapy

  • FulvestrantCombination product

    Endocrine Therapy

  • MidazolamOther

    Benzodiazepine

  • EnzalutamideCombination product

    Androgen Receptor inhibitor

  • GiredestrantCombination product

    Endocrine Therapy

  • TamoxifenCombination product

    Endocrine Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation PortionTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Incidence of clinically significant AEsTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
  3. Incidence of clinically significant laboratory assessmentsTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
  4. Incidence of clinically significant abnormal vital and ECG parametersTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
  5. Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
  6. Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
  7. Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
  8. Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  9. Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  10. Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  11. Steady State Maximal Concentration (Cmax,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  12. Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  13. Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  14. Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
  15. Steady State Maximal Concentration (Cmax,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
  16. Steady State Time to Maximum Plasma Concentration (Tmax,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
  17. Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
  18. Steady State Minimum Plasma Concentration (Cmin,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Ellison Institute

    Los Angeles, California · Recruiting

  • Smilow Cancer Hospital - Yale New Haven Health

    New Haven, Connecticut · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Phase 1 Unit

    New Haven, Connecticut · Recruiting

  • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital - Trumbull

    Trumbull, Connecticut · Recruiting

  • Brigham & Women's Hospital

    Boston, Massachusetts · Active not recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • Dana Farber Cancer Institute- Chestnut Hill

    Newton, Massachusetts · Active not recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - West Houston

    Houston, Texas · Recruiting

  • Fundación Respirar

    Buenos Aires, Argentina · Active not recruiting

  • Clínica Universitaria Reina Fabiola

    Córdoba, Argentina · Active not recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer

    La Rioja, Argentina · Active not recruiting

  • Hospital Británico de Buenos Aires

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Active not recruiting

  • Fundación Cenit Para La Investigación En Neurociencias

    CABA, Ciudad Autã³noma de Buenos Aires, Argentina · Active not recruiting

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China · Active not recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Active not recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Active not recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Active not recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Active not recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Active not recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Active not recruiting

  • Oaxaca Site Management Organization

    Oaxaca City, Mexico · Active not recruiting

  • COI Centro Oncologico Internacional S.A.P.I. de C.V.

    Mexico City, Mexico City, Mexico · Active not recruiting

  • Hospital MAC Periferico Sur

    Mexico City, Mexico City, Mexico · Active not recruiting

  • INCAN

    Mexico City, Mexico City, Mexico · Active not recruiting

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, Mexico · Active not recruiting

  • Hospital Reforma

    Oaxaca City, Oaxaca, Mexico · Active not recruiting

  • Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA

    Bratislava, Slovakia · Active not recruiting

  • Narodny onkologicky ustav

    Bratislava, Slovakia · Active not recruiting

  • Fakultna nemocnica s poliklinikou Nove Zamky

    Nové Zámky, Slovakia · Active not recruiting

  • Sarah Cannon Research Institute UK

    London, United Kingdom · Active not recruiting

  • The Christie Hospital NHS Foundation Trust

    Manchester, United Kingdom · Active not recruiting

  • Cancer Research UK Edinburgh Centre

    Edinburgh, Edinburgh, CITY of, United Kingdom · Active not recruiting

  • St Bartholomew's Hospital

    London, London, CITY of, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.